Pharma
Stocks Outlook for the week – 02 to 06.05.2016
Mixed; Lupin may gain, Wockhardt
result eyed
( www.rupeedesk.in )
Stocks of pharmaceutical companies
are seen trading mixed next week, with Lupin Ltd likely to
extend gains on expectation of strong
Jan-Mar earnings and optimism due to recent product launches in the US. On
Thursday, Lupin said it has reintroduced Methergine oral tablets in 0.2 mg
strength in the US, which will bolster its branded drug portfolio. Methergine
is the only US Food and Drug Administration-approved oral uterotonic and is a
preferred oral agent in the prevention and
management of postpartum haemorrhage.
This week, shares of Lupin rose 3%. Stocks of Aurobindo
Pharma Ltd are expected to trade
range bound in the coming days after a 2.5% fall this week.
While sporadic upside movements may
be triggered by any new product approvals in the US, gains
are likely to be limited. Market
participants will await Jan-Mar earnings of Wockhardt Ltd, Pfizer Ltd,
Sun Pharma Advanced Research Co Ltd,
and Aarti Drugs Ltd next week. We expects Wockhardt to
post a consolidated net profit of 380
mln rupees in Jan-Mar, up 11.5% from a year ago, and net sales of 11.33 bln
rupees, up 5.0% on year. Pfizer's net profit in Jan-Mar is seen at 593 mln
rupees, up 38.9% on year, and net sales are expected to rise 11.9% to 5.10 bln
rupees. The pharmaceutical
pack has been in a downward
correction phase in the past two months due to regulatory headwinds,
but within the sector, Sun Pharmaceutical
Industries Ltd is favourably placed and looks attractive at
current levels.
We believe that the stock's
risk-reward ratio is decent and gives medium-term investors an opportunity to
buy. It expects a 15% upside in the stock in six months. We believe the stock
is
poised to resume its medium-term
uptrend after concluding a healthy corrective phase.